ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

TargetBeta

GIPR

gastric inhibitory polypeptide receptor · Glucagon receptor family

13 programs in company-led studies act on GIPR, from 9 companies: 6 in phase 3, 1 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyActs asFurthest phaseStudiesAlso acts onRead from
TirzepatideruleEli Lillyagonistphase 47219 runningGLP1RChEMBL
brenipatideEli Lillyagonistphase 31916 runningGLP1Ra judged reading
UBT251The United Laboratories Internationalagonistphase 31212 runningGCGR, GLP1Ra judged reading
retatrutideruleEli Lillyagonistphase 33311 runningGCGR, GLP1RChEMBL
olatorepatideHansoh Pharmaceutical Groupagonistphase 3127 runningGLP1Ra judged reading
enicepatideHoffmann-La Rocheagonistphase 3107 runningGLP1Ra judged reading
VK2735ruleViking Therapeuticsagonistphase 385 runningGLP1Rthe studies' text
macupatideEli Lillyagonistphase 284 running–a judged reading
BI 3034701Boehringer Ingelheimagonistphase 264 runningGLP1R, NPY2Rthe company's pipeline
HRS-4729Jiangsu HengRui Medicine–phase 254 runningGCGR, GLP1Rthe company's pipeline
NNC0519-0130Novo Nordiskagonistphase 2111 runningGLP1Ra judged reading
GIPR Agonist LY3537021Eli Lillyagonistphase 231 running–the company's pipeline
NA-931ruleBiomed Industriesagonistphase 231 runningGLP1R, IGF1the studies' text

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.